R.J. Hohl
Impact in
- Hematology top 10%
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Multiple Myeloma Research and Treatments
-
- Hemoglobinopathies and Related Disorders
Papers in
-
- Erythropoietin and Anemia Treatment 4
- Blood groups and transfusion 2
- Hematopoietic Stem Cell Transplantation 2
- Platelet Disorders and Treatments 1
-
- Protein Degradation and Inhibitors 1
- Cancer therapeutics and mechanisms 1
- Co-authors
- Robert L. Schmidt (4 shared papers)John A. Widness (4 shared papers)P. Veng‐Pedersen (4 shared papers)Sunny Chapel (3 shared papers)Nidal Al‐Huniti (3 shared papers)Dean F. Bajorin (2 shared papers)Susan Halabi (2 shared papers)Eric J. Small (2 shared papers)
- Journals
- Journal of Pharmacology and Experimental Therapeutics (2 papers)Journal of Clinical Oncology (2 papers)Clinical Pharmacology & Therapeutics (2 papers)Blood (1 paper)Annals of Oncology (1 paper)
- Partner nations
- United StatesIndiaMexico
In The Last Decade
R.J. Hohl
10 papers receiving 181 citations
Peers
Comparison fields: 5 of 47
- Hematology 105
- Genetics 29
- Biochemistry 14
- Oncology 38
- Pediatrics, Perinatology and Child Health 21
Countries citing papers authored by R.J. Hohl
This map shows the geographic impact of R.J. Hohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.J. Hohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.J. Hohl more than expected).
Fields of papers citing papers by R.J. Hohl
This network shows the impact of papers produced by R.J. Hohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.J. Hohl. The network helps show where R.J. Hohl may publish in the future.
Co-authors
The 25 scholars most cited alongside R.J. Hohl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2001 | 53 | |
| 2 | 2008 | 39 | |
| 3 | 2004 | 21 | |
| 4 | 2007 | 21 | |
| 5 | 2006 | 16 | |
| 6 | 2003 | 15 | |
| 7 | 2003 | 7 | |
| 8 | 2009 | 7 | |
| 9 | 2006 | 3 | |
| 10 | Phase 1 study of irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy | 2001 | 2 |
About R.J. Hohl
R.J. Hohl is a scholar working on Hematology, Molecular Biology, Pulmonary and Respiratory Medicine, Surgery and Oncology, having authored 10 papers that have together received 184 indexed citations. Recurring topics across this work include Erythropoietin and Anemia Treatment (4 papers), Blood groups and transfusion (2 papers), Bladder and Urothelial Cancer Treatments (2 papers), Hematopoietic Stem Cell Transplantation (2 papers), Advanced Radiotherapy Techniques (1 paper), Protein Degradation and Inhibitors (1 paper), Cancer therapeutics and mechanisms (1 paper) and Platelet Disorders and Treatments (1 paper). The work is most often cited by research in Hematology (105 citations), Genetics (29 citations), Biochemistry (14 citations), Oncology (38 citations) and Pediatrics, Perinatology and Child Health (21 citations). R.J. Hohl has collaborated with scholars based in United States, India and Mexico. Frequent co-authors include Robert L. Schmidt, John A. Widness, P. Veng‐Pedersen, Sunny Chapel, Nidal Al‐Huniti, Dean F. Bajorin, Susan Halabi, Eric J. Small, J. N. Atkins and Jonathan E. Rosenberg. Their work appears in journals such as Journal of Pharmacology and Experimental Therapeutics, Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics, Blood and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.